Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Trading Statement

30 Nov 2005 07:04

Original Investments PLC30 November 2005 Original Investments PLC ("Original Investments" or "the Company") Acrobot update An innovative medical device, enabling orthopaedic surgeons to accurately planand perform hip resurfacing surgery, has been granted a CE-mark by BSI'sCertification Panel. The surgical navigation product has been developed by TheAcrobot Company ("Acrobot") in which Original Investments, the AIM-quotedinvestment company, has a 25% shareholding. The device has been developed incollaboration with Corin Group PLC ("Corin"), and the CE-mark is themanufacturer's guarantee that the device meets all the required Europeanmanufacturing and safety standards. Acrobot develops surgical systems for minimally-invasive, bone-conservingorthopaedic surgery. The new device, called Acrobot(R) Navigation, is beingcommercialised by Corin, under the name of Wayfinder(R), to enable accurateimplantation of the company's metal on metal hip resurfacing implant.Clinical trials are to start immediately at a London hospital. Justin Cobb,Professor of Orthopaedics at Imperial College, will lead the alpha site. Twoadditional sites in the UK and a third in Australia will start evaluation of theAcrobot(R) Navigation system in the second quarter of 2006. The device will bein wider use from the second half of 2006. The Acrobot(R) Navigation system gives the surgeon the ability to accuratelyimplant hip resurfacing prostheses in a minimally invasive procedure. It differsfrom competitive products by using mechanical tracking rather than optical orelectromagnetic technologies, giving it a higher accuracy at a lower cost.Acrobot believes that this unique selling point will increase the use of thetechnology, making it accessible to a larger number of surgeons and patients.The Acrobot(R) Navigation system has been developed by the Acrobot team at thecompany's laboratories in London. Acrobot is seeking licensees and distributorsfor applications of Navigation to other orthopaedic procedures. It is the secondof a number of related products to be produced by Acrobot, having launched theAcrobot(R) Planner software and service last month. A third product planned forlaunch in 2006 is the Acrobot(R) Hands-On Robotic System, which has already beensuccessfully proven in clinic for unicompartmental knee arthroplasty. Enquiries to: Dr. Paula Gomes, Director of OperationsThe Acrobot Company Ltd, Tel: +44 (0)20 7403 5866, Email:enquiries@acrobot.co.ukor Terry Bond, Managing Director, Original Investments PLC 44 (0) 1235 834734.Email: tb@originalinvestments.com About The Acrobot Company Ltd The Acrobot Company Ltd develops precision surgical systems for minimallyinvasive, bone conserving, orthopaedic surgery. The Company was founded sixyears ago by Imperial Innovations as a collaboration to combine the skills ofclinicians and academics Using proprietary surgical planning software andstate-of-the-art Hands-On Robotics(TM), and Passive Constraint Navigation(TM)systems, Acrobot's products assist surgeons in achieving better patient outcomesby improving surgical precision and reducing surgical errors, while loweringoverall procedure cost. About Original Investments PLC Original Investments PLC, formerly called BioProjects International PLC, isquoted on the AIM market of the London Stock Exchange. The Company specializesin providing finance for early-stage companies that can demonstrate immediategrowth prospects and significant financial potential. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.